6TH INTERNATIONAL SYMPOSIUM
ON ACUTE PROMYELOCYTIC LEUKEMIA
Rome, September 29 - October 2, 2013
PRELIMINARY PROGRAM
Sunday, September 29, 2013
2.30 pm
Registration opens
3.00-4.00 Satellite Symposium: Diagnostic tools and targeted therapies in
myeloid malignancies
Chairs: F. Pane (I), P. Musto (I)
Prognostic Classification and Response Monitoring using Molecular Diagnostics in
AML: Current Results and Developments
C. Thiede (D)
New EuroFlow tools for the immunophenotypic characterization of acute
promyelocytic leukemia at diagnosis and during follow-up
A. Orfao (E)
Molecular pathways and targeted therapies in myelodysplasia
V. Santini (I)
4.00 pm - 5.30 pm
Educational session (Biology, Diagnosis and Management of APL)
(in Spanish, repeated in English on Tuesday).
Speakers:
Patogenesis, Diagnosis and Monitoring
F. Lo Coco (I)
Front-line Therapy
M.A. Sanz (E)
Therapy of Relapse
P. Fenaux (F)
5.30-6.00 pm Coffee break
6.00 pm – 6.30 pm
Opening Ceremony
6.30 pm – 7.20 pm
Keynote Lecture
“The APL Genome”
T. Ley (USA)
7.30 pm
Welcome Cocktail
Monday, September 30, 2013
8.00 am
Registration opens
9.00 am – 10.00 am
Plenary Session I. Experimental models and targeted therapy
Chairs: H. de Thé (France), F. Grignani (Italy)
Unlocking the Therapeutic Potential of Retinoic Acid in AML
A. Zelent (UK)
Targeted therapy: the new lease of life for conquering leukemia
S.J. Chen (China)
Molecular basis for APL eradication by the retinoic arsenic combination
H. de Thé (France)
10.00 am – 10.20 am Coffee break
10.20 am - 12.10 pm
Plenary Session II. Tracking leukemia stem cells and minimal residual
disease
Chairs: C. Thiede (Germany), G. Saglio (Italy)
MRD in APL: implications of molecular and cellular methods
C. Chomienne (France)
Tracking therapy-resistant clones
D. Grimwade (UK)
Leukemia-initiating cells in APL
P.G. Pelicci (Italy)
Deconstructing the molecular genetics of Acute Promyelocytic Leukemia and its
therapeutic implications
P.P. Pandolfi (USA)
12.10 pm -1.30 Lunch
1.30 pm – 3.30 pm
Plenary Session III. Management of APL in Developing Countries
Chairs : B. Löwenberg (NL), N. Berliner (USA)
Challenges and strategies to improve the outcome of APL in developing countries
E. Rego (Brazil)
The challenge of standardizing care for APL in India
M. Chandy (India)
Selected papers (max 4)
3.30 pm – 3.50 pm Coffee break
3.50 pm- 5.30 pm
Poster Viewing
…………………………………………………………………………………………………
Tuesday, October 1st, 2013
8.30 am – 10.00 am
Educational session (Biology, Diagnosis and treatment) (English)
Patogenesis, Diagnosis and Monitoring
F. Lo Coco (I)
Front-line Therapy
M.A. Sanz (E)
Therapy of Relapse
P. Fenaux (F)
10.00 am – 10.40 am
Plenary Session IV - Early death in APL – Data from real world
Chairs: M.A. Sanz, J. Rowe (Israel)
An update from the Swedish Registry - has early death rates in APL improved?
S. Lehmann (Sweden)
Early death in APL: Real World Data and the Way Forward
M.S. Tallman (USA)
Selected papers
10.40- 11.00 Coffee break
11.00 am – 12.50 pm
Plenary Session V - The APL coagulopathy.
Chairs: G. Avvisati (I), A. Falanga (I)
Molecular basis of the APL coagulopathy
A. Falanga (I)
Incidence and risk factors for tromboischemic complications in APL
P. Montesinos (Spain)
Selected papers (max 2)
12.00 pm– 1.00 pm
Plenary Session VI - Oncogenic signalling and epigenetics
Chairs: M. Alcalay (I) P.P. Pandolfi (USA)
The epigenetic role of microRNA-223 in normal hematopoiesis and acute myeloid
leukemias
C. Nervi (I)
A novel role of chromatin modulation in retinoid-resistant APL.
W.H. Miller (Canada)
1.00 pm– 2.00 pm Lunch
2.00 pm - 3.20 pm
Plenary Session VI - Update on first line therapy (I)
Chairs: L. Degos (F), F. Mandelli (I)
The GIMEMA pathway to the cure of APL.
G. Avvisati (I)
The Australasian Leukaemia and Lymphoma Group APML4 trial – update on APL
treatment down under
H. Iland (Australia)
Improvements with risk-adapted PETHEMA protocols in newly diagnosed APL
M.A. Sanz (Spain)
Combined ATRA and arsenic treatment as front-line therapy for APL: experience
from China
J. Hu (China)
3.20 pm - 3.40 pm Coffee break
3.40 pm – 5.10 pm
Plenary Session VII - Update on first line therapy (II)
Chairs: M. Tallman (USA), S. Amadori (I)
Strategies to improve clinical outcome of upfront therapy with arsenic trioxide
without increasing myelosuppression and maintaining low toxicity
V. Mathews (India)
Clinical Trials in Diseases with High Cure Rates: Treatment of APL Without
Chemotherapy as an Example
E. Estey (USA)
An update of French- Swiss- Belgian trials in newly diagnosed APL
P. Fenaux (France)
From the UK: Less is just as good
A. Burnett (UK)
Wednesday October 2nd , 2013
8.30 am – 9.30 am
Plenary Session VIII - Management of Relapse and Role of Stem Cell
Transplantation
Chairs: G. Ehninger (Germany), A. Burnett (UK)
Results of the European Registry of Patients with Relapsed APL (PROMYSE)
E. Lengfelder (Germany)
Role of arsenic trioxide for the management of relapsed APL patients
M. Breccia (Italy)
Role of stem cell transplantation
J. Sanz (Spain)
9.30 am – 10.30 am
Plenary Session IX - APL as a second tumor and t-MN after APL
Chairs : G. Leone (Italy), U. Platzbecker (germany)
Clinical, pathological, and cytogenetic features of therapy-related acute
promyelocytic leukemia
R.A. Larson (USA)
APL secondary to non-malignant disorders
S.K. Hasan (India)
Therapy-related myeloid neoplasms after APL: the PETHEMA experience
P. Montesinos (Spain)
10.30 am -10.50 am Coffee break
10.50 am -11.50
Pediatric and elderly APL
Chairs : R. Schlenk (Germany), E. Estey (USA)
Acute Promyelocytic Leukemia in the elderly: beyond the age
R. Latagliata (Italy)
Pediatric and elderly APL: The French-Belgian-Swiss Experience
L. Adés (France)
+ Selected papers
12.00 pm
Conclusive Remarks
F. Lo-Coco (Italy), M.A. Sanz (Spain)